OpenAlex
PricingAboutJobs
Log inGet started
Work

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

HTML

Year: 2020
Type: article
Source: Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00182
Authors: Justin T. Ernst, Peggy A. Thompson, Christian Nilewski, Paul A. Sprengeler, Samuel Sperry, Garrick Packard, Theodore Michels, Alan Xiang, Chinh Tran, Christopher J. Wegerski, Boreth Eam, Nathan P. Young, Sarah Fish, Joan Chen, Haleigh Howard, Jocelyn Staunton, Jolene Molter, Jeff Clarine, Andres Nevarez, Gary G. Chiang, Jim R. Appleman, Kevin R. Webster, Siegfried H. Reich
Institutions: eFFECTOR Therapeutics (United States), Genentech, Gossamer Bio (United States), WuXi AppTec (United States), Casma Therapeutics (United States), Providence Portland Medical Center, Frontier Medicines (United States)
Language: English

Topic: RNA and protein synthesis mechanisms
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: eIF4A, DEAD-box RNA helicase, eIF4F, cap-dependent translation, anticancer agents, ligand-based drug design, anticancer activity
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3031081298
FWCI: 5.017
Cites: 41
Cited by: 159
Related to: 10
Parts: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security